2013-02-27 17:42:26 -

Santhera Pharmaceuticals Holding AG /
Santhera to Discontinue Sale of Catena® in Canada
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 

Liestal, Switzerland, February 27, 2013 - Santhera Pharmaceuticals (SIX: SANN)
announced today the voluntary withdrawal of Catena(®) from the Canadian market.
This decision follows review of additional data from clinical trials in patients
with Friedreich's Ataxia, and subsequent consultation with Health Canada.



Santhera Pharmaceuticals (Canada), Inc, the holder of conditional market
authorization (Notice of Compliance with conditions, NOC/c) in Canada for
Catena(®) in the treatment of Friedreich's Ataxia, will discontinue sales
effective April 30, 2013. Catena(®) had been conditionally authorized in Canada
in July 2008 on the basis that it demonstrated promising evidence of clinical
effectiveness for the treatment of patients with Friedreich's   Ataxia. One of the
conditions of authorization was to provide confirmatory evidence of this
effectiveness in further clinical studies. However, the data from the program of
studies conducted were not considered by Health Canada to provide such
confirmation, and following consultation between Santhera and Health Canada,
Santhera has agreed to voluntarily withdraw Catena(®) from the Canadian market.



No specific safety issues were identified that have prompted this action, and
the withdrawal does not preclude the submission of a new application for market
authorization in the future. A communication strategy for treating physicians
and patients has been agreed with Health Canada.



                                     * * *

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan neuromuscular and mitochondrial diseases,
areas of high unmet medical need with no current therapies. For further
information, please visit www.santhera.com.



Catena(®) is a trademark of Santhera Pharmaceuticals.



For further information, contact

Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com



Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.






News Release Health Canada: 
 hugin.info/137261/R/1681302/549603.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Santhera Pharmaceuticals Holding AG via Thomson Reuters ONE
[HUG#1681302]